NCT01448902

A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

A Study Of The Effects Of OC000459 On Responses To Allergen Challenge In The Vienna Chamber In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 36 (actual)
• Sponsor: Oxagen Ltd · Industry
• Sex: Male
• Age: 18 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The study will assess the efficacy of OC000459 200 mg twice daily orally in comparison to placebo when subjects are challenged in the Vienna Challenge Chamber for 6 hours. This is a randomised, double blind, placebo controlled, two way crossover evaluation. There will be a screening period of up to three weeks and a washout period of at least one week between the two treatment periods. There will be a follow up one to three weeks after the last dose of study drug.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	OC000459	OC000459 200mg bid for 8 days
DRUG	Placebo	Placebo bid for 8 days

Timeline

• Start date: 2007-03-01
• Primary completion: 2007-05-01
• Completion: 2007-05-01
• First posted: 2011-10-07
• Last updated: 2011-10-07

Locations

1 site across 1 country: Austria